Leronlimab failed to meet any of their CD10 or CD12 primary or secondary endpoints -- that proof it works. Data dredging subgroups are not going to be credible -- was not part of the original trial protocol, didn't have a significant sample size, and the company also manipulated the p-values to claim significance when there wasn't any. That's why the FDA Statement was issued to correct the erroneous information that Cytodyn was releasing in their press releases and 8K SEC filing. This than motivated the SEC and DOJ to start an investigation into the company for stock fraud.
Subgroup data dredged data from a failed trial is not considered credible and certainly is not acceptable for regulatory filing.
Market Data 
Markets 
AI
